Last mentioned: Mar 12, 2026
BofA Target Increase
Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
Institutional Rebalancing
Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
Fast-Track Approval
FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
FDA Approval & 12-Month High
JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.